Hernexeos zongertinib
宗格替尼
Drug Class
HER2 tyrosine kinase inhibitorHER2 酪氨酸激酶抑制剂
Mechanism
Selectively inhibits the kinase domain of HER2 while sparing wild-type EGFR, blocking downstream oncogenic signaling.选择性地抑制突变型HER2的激酶活性结构域,而较少影响野生型EGFR,从而阻断下游致癌信号通路的传导。
Approved Indication
Advanced HER2 tyrosine kinase domain-mutated non-squamous non-small cell lung cancer, per its FDA approval.根据美国FDA批准,适用于携带HER2酪氨酸激酶结构域突变的晚期非鳞状非小细胞肺癌。
What This Means For Patients
Hernexeos is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.Hernexeos(宗格替尼)目前未通过中国大陆零售药房渠道销售。优健云可协助安排购买渠道,药品由香港采购发货;如有需要,可协调来华后的临床用药支持。具体供应及患者适用性以医疗预检评估为准。
Regulatory Approvals
- FDA — Approved (2025) — Sources
Pivotal Clinical Evidence
- Beamion LUNG-1 — Heymach et al., N Engl J Med 2026 (NCT04886804) — Sources